Tandem Mobi Insulin Pump Now Compatible with Dexcom G7 CGM: A Breakthrough in Diabetes Management
SAN DIEGO’ - Tandem Diabetes Care, Inc. (Nasdaq: TNDM) and Dexcom, Inc. (Nasdaq: DXCM) today announced a significant advancement in diabetes management, unveiling the full compatibility of the Tandem Mobi insulin pump with the Dexcom G7 Continuous Glucose Monitoring (CGM) System. This announcement underscores Tandem Mobi’s status as an innovative leader in automated insulin delivery (AID) systems, having launched earlier this year in the United States.
A Technological Milestone’
Tandem Mobi, celebrated as the world’s smallest and most durable AID system, already supports the Dexcom G6 CGM. The addition of Dexcom G7 compatibility further cements its position at the forefront of diabetes technology. The Control-IQ technology at the heart of Tandem Mobi provides an advanced level of automation, significantly easing the daily burden of diabetes management for users.
“People living with diabetes can now enjoy more options and greater convenience, thanks to this pivotal update,” said John Sheridan, President and CEO of Tandem Diabetes Care. “We are dedicated to improving lives through innovation and by providing best-in-class diabetes management solutions. The inclusion of the Dexcom G7 CGM adds another layer of ease and precision for our users.”
Advantages of the Tandem Mobi and Dexcom Integration’
The integration of the Tandem Mobi pump with Dexcom’s G7 and G6 systems is a synergistic merger of cutting-edge technologies, bringing numerous benefits:
’Increased Precision’: The Dexcom G7 offers quicker and more accurate glucose readings, further enhancing the Control-IQ technology’s ability to make real-time adjustments to insulin delivery.
’User-Friendly Design’: The Tandem Mobi pump’s compact design and user interface are complemented by the Dexcom G7’s streamlined setup and ease of use, offering a more seamless experience.
’Connectivity and Data Utilization’: With integration into both CGM platforms, users can leverage the power of real-time data to make informed management decisions and enjoy improved health outcomes.
Strategic Alliance to Benefit Users’
Kevin Sayer, Chairman, President, and CEO of Dexcom, elaborated on the collaboration’s impact, stating, This partnership aligns with our mutual goal ’ empowering people living with diabetes through advanced, user-friendly technology. The integration of Dexcom G7 with Tandem Mobi not only simplifies diabetes management but also enhances the quality of life for countless individuals.
Setting a New Standard in Diabetes Care’
The collaboration between Tandem Diabetes Care and Dexcom continues to push the boundaries of what’s possible in diabetes technology. By offering compatibility with both Dexcom G6 and G7 CGM systems, Tandem Mobi stands out as the most versatile, patient-centered AID system available. This development reflects the relentless pursuit of excellence by both companies to deliver superior diabetes care solutions.
As the landscape of diabetes management evolves, innovations like the Tandem Mobi and Dexcom partnership play a crucial role in providing accessible and effective care. For those living with diabetes, the future is undoubtedly bright with these advancements at their disposal.
Conclusion’
The breakthrough compatibility of the Tandem Mobi insulin pump with the Dexcom G7 CGM system represents a significant leap forward in diabetes technology. By offering robust automation paired with highly accurate continuous glucose monitoring, this integration sets a new benchmark in effective and user-friendly diabetes management, promising enhanced health outcomes and a better quality of life for users.
Comments